Loading...
•
Jun 30
•/
Organigram Q3 2025 Earnings Report
Organigram posted record Q3 2025 results with significant revenue and adjusted EBITDA growth driven by acquisitions and international expansion.
Key Takeaways
Organigram achieved its second consecutive quarter of record revenue in Q3 2025, led by the Motif acquisition, robust international sales, and U.S. market entry. Despite a net loss, the company saw strong adjusted EBITDA and positive free cash flow.
Net revenue surged 72% year-over-year to $70.8 million.
Adjusted EBITDA rose 64% to $5.7 million.
Free cash flow reached $5.0 million compared to a loss of $4.8 million last year.
International revenue increased 208% to $7.4 million.
Organigram
Organigram
Organigram Revenue by Geographic Location
Revenue by Geographic Location
International Revenue
CapyFin.com Forward Guidance
Organigram expects continued improvement in adjusted gross margins, sustained free cash flow, and increased international revenue following recent acquisitions and U.S. market expansion.
Positive Outlook
- Continued international revenue growth with 208% YoY increase
- U.S. expansion began generating revenue with distribution in 25 states
- Motif synergies of $4.2M to date and tracking toward $15M
- Second consecutive quarter of positive Free Cash Flow
- Record Moncton harvest averaging over 29% THC potency
Challenges Ahead
- Net loss of $6.3 million in the quarter
- SG&A expenses increased 70% YoY
- Adjusted gross margin % decreased to 34% from 36%
- Cash and short-term investments declined 36% YoY
- No EU-GMP certification yet for Moncton facility